Anti-Granulocyte–Macrophage Colony–Stimulating Factor Monoclonal Antibody Gimsilumab for COVID-19 Pneumonia: A Randomized, Double-Blind, Placebo-controlled Trial

• DOI: 10.1164/rccm.202108-1859oc
• Publication Date: 2022-03-15T17:41:05Z
• Authors: Gerard J. Criner; Frederick M. Lang; Robert L. Gottlieb; Kusum S. Mathews; Tisha S. Wang; Todd W. Rice; Deepu Madduri; Shashi Bellam; Robert Jeanfreau; Amy H. Case; Marilyn K. Glassberg; George Marshall Lyon; Kareem Ahmad; Robert Mendelson; J. Michael DiMaio; MaryAnn P. Tran; Cedric W. Spak; Jamil A. Abbasi; Steven G. Davis; Shekhar Ghamande; Steven Shen; Lisa Sherman; Simon Lowry
• Keywords: 2019-20 coronavirus outbreak

GM-CSF (granulocyte-macrophage colony-stimulating factor) has emerged as a promising target against the hyperactive host immune response associated with coronavirus disease (COVID-19).